Business Wire

CA-GRINDR

Share
Grindr Launches In-App Access to Sexual Health and Safety Resources in 30 Countries Around the World

Grindr Inc. (NYSE:GRND), the premier LGBTQ+ social connector, today announced it has partnered with several organizations to launch in-app access to sexual health and safety resources for its users in 30 countries around the world. This wide-reaching program is led by Grindr for Equality, the company’s social impact initiative. Grindr users across 30 countries, including Brazil, Kenya, Spain, and Namibia, are now able to access these vital sexual health and safety resources directly through a side drawer on the Grindr app’s home screen, gaining localized and real-time information on the issues that matter to them the most.

Since 2015, Grindr for Equality has worked towards a world where the lives of Grindr users and the global LGBTQ+ community are free, equal, and just, advancing initiatives that impact communities on issues such as safety and sexual health. Lack of access to HIV testing is one of the biggest obstacles in the fight against the global HIV epidemic, posing a particular burden for some Grindr users, such as those living in rural areas or those who are not “out” to their families. Additionally, anti-LGBTQ+ legislation threatens the safety of members of the queer community every day by criminalizing their fundamental identities. With its new partnerships and its ongoing work, Grindr for Equality aims to empower users with real-time access to critical information that helps combat this adversity.

The new safety and sexual health resources available on the Grindr platform are led by Grindr for Equality’s partnership with European Test Finder, a free online tool that helps users find nearby locations for testing and treatment of HIV, Tuberculosis, Hepatitis B and C, and other STIs across the WHO European region. Grindr users across 24 countries supported by European Test Finder, including Austria, Belgium, Cyprus, France, Serbia, Slovakia, and Ukraine, are now able to quickly access vital public health services directly on Grindr. Grindr for Equality is also partnering with Ceska spolecnost aids pomoc, IntraHealth Namibia, IVOR Foundation, and The Love Tank to make additional sexual and mental health resources available to Grindr users in Czechia, Namibia, Bulgaria, and the United Kingdom, respectively.

In Brazil, Grindr for Equality is partnering with Ministério da Saúde, Departamento de HIV, Aids, Tuberculose, Hepatites Virais e Infecções Sexualmente Transmissíveis to provide in-app access to Onde encontrar a PrEP, a PrEP service locator. Grindr for Equality is also partnering with GALCK+ to provide Grindr users in Kenya with in-app access to Know Your Rights, a safety page designed to empower the Kenyan LGBQ community by informing them of their rights.

“Grindr is proud to partner with groups like CHIP and the EuroTEST Initiative that are hosting the European Test Finder to increase access to essential sexual health and safety resources for users around the world,” said Steph Niaupari of Grindr for Equality. “We’ve seen how in-app resources can help drive meaningful public health outcomes for the LGBTQ+ community, and we look forward to expanding the impact Grindr is able to achieve by providing a wider range of sexual health and safety resources to more of our global users.”

“We are thrilled to partner with Grindr to widen access to crucial testing and treatment for life-altering conditions such as HIV, Tuberculosis, and Hepatitis,” said Cæcilie Bom Kahama, project coordinator for the European Test Finder, at the secretariat of the EuroTEST Initiative, at CHIP in Denmark. “By helping more individuals quickly and easily access these public health services, Grindr is taking concrete steps to promote early diagnosis and care. We are grateful for the company’s leadership on this matter and hope this will encourage more people to test regularly and ultimately help reduce overall transmission.”

Today’s announcement builds on the success of Grindr for Equality’s existing partnerships to distribute free at-home HIV test kits directly to Grindr users across a growing list of countries including Georgia, Ireland, New Zealand, and the United States, as well as the City of London. In partnership with organizations including Building Healthy Online Communities, these programs have distributed more than 440,000 test kits to date. Grindr for Equality plans to launch similar initiatives and bring additional safety, sexual health, and advocacy resources to more Grindr users and members of the LGBTQ+ community around the world.

About Grindr Inc.

With more than 13.7 million monthly active users, Grindr has grown to become the Global Gayborhood in Your Pocket, on a mission to make a world where the lives of our global community are free, equal, and just. Available in 190 countries and territories, Grindr is often the primary way for its users to connect, express themselves, and discover the world around them. Since 2015 Grindr for Equality has advanced human rights, health, and safety for millions of LGBTQ+ people in partnership with organizations in every region of the world. Grindr has offices in West Hollywood, the Bay Area, Chicago, and New York. The Grindr app is available on the App Store and Google Play.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240711785938/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye